The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ELEVATION ONCOLOGY INC COM 28623U101   2,251,635 2,370,142 SH   SOLE   2,370,142 0 0
HILLEVAX INC COM 43157M102   9,350,782 558,923 SH   SOLE   558,923 0 0
ICOSAVAX INC COM 45114M109   27,871,210 3,510,228 SH   SOLE   3,510,228 0 0
JASPER THERAPEUTICS INC COM 471871103   2,826,405 5,852,982 SH   SOLE   5,852,982 0 0
KEZAR LIFE SCIENCES INC COM 49372L100   5,834,125 828,711 SH   SOLE   828,711 0 0
TALARIS THERAPEUTICS INC COM 87410C104   2,991,258 2,932,606 SH   SOLE   2,932,606 0 0
VENTYX BIOSCIENCES INC COM 92332V107   24,473,472 746,370 SH   SOLE   746,370 0 0